Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07206589 · ClinicalTrials.gov registry record · NA
Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial
A NA study, sponsored by Mayo Clinic.
- Not yet
- Registry status
- NA
- Development phase
- 1,010
- Enrollment target
NCT07206589: Clinical Trial NA study, sponsored by Mayo Clinic.
NCT07206589 is a NA study that has not yet begun recruiting, run by Mayo Clinic. The registered enrollment target is 1,010 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07206589, a NA study, has not yet begun recruiting, sponsored by Mayo Clinic.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 1,010 participants
- Enrollment target
Study Summary
This clinical trial studies how well minimally invasive approaches (an artificial intelligence \[AI\] powered risk tool, nurse navigation, and a sponge on a string \[SOS\] test) work in diagnosing patients with Barrett's esophagus (BE) and esophageal cancer. Esophageal cancer has a poor 5-year survival rate when diagnosed after onset of symptoms. While rising, incidence of esophageal cancer remains too low to screen the entire population. BE is a condition in which the cells lining the lower part of the esophagus have changed or been replaced with abnormal cells that could lead to esophageal cancer. Currently, patients are screened for BE based on certain risk factors (reflux, age \> 50 years, White race, family history of esophageal cancer, obesity, male sex, and smoking), followed by endoscopies and surgery for treatment. These standard procedures may result in under-recognition of BE risk due to inaccurate and difficult to use risk assessment tools, high cost, invasiveness, low access to endoscopy, and sub-optimal recognition of abnormal cells during routing endoscopy. An AI powered risk tool that integrates symptoms, health history, and laboratory values from electronic health record data may more accurately assess BE and esophageal cancer risk that manual assessment. The BE-SOS screening test combines a swallowable cell collection device with assessment of DNA, which may more accurately diagnose abnormal cells. Nurse navigation involves trained personnel assisting individuals through the screening process and completing the follow-up diagnostic test if the screening test is positive. Navigators address cultural, social, access, and logistical barriers to screening. Nurse navigation may increase completion rates of diagnostic procedures following a positive screening test. These minimally invasive approaches may enable higher rates of BE screening than currently being accomplished.
Primary Outcome
Assessed as the proportion of patients who complete BE screening. This is determined as the number of patients who complete a sponge on a string (SOS) BE screening test or endoscopy screen, divided by the number of screen eligible patients in each group.
Interventions
- OTHER Navigation
- PROCEDURE Endoscopic Procedure
- OTHER Cancer Screening
- OTHER Computer-Assisted Intervention
- BEHAVIORAL Health Risk Assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,010 participants |
| Start Date | 2026-12-01 |
| Est. Completion | 2030-07-31 |
| Phase | NA |
What is known before NCT07206589 opens enrollment
NCT07206589 is an interventional study that assigns participants to a tested intervention. Its 1,010 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 5 interventions - of which Navigation is the first listed.
NCT07206589 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07206589 about?
NCT07206589 is a clinical study titled "Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial". This clinical trial studies how well minimally invasive approaches (an artificial intelligence \[AI\] powered risk tool, nurse navigation, and a sponge on a string \[SOS\] test) work in diagnosing patients with Barrett's esophagus (BE) and esophageal cancer. Esophageal cancer has a poor 5-year survi...
What is the current status of trial NCT07206589?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 1,010 participants. The study started on 2026-12-01. Estimated completion is 2030-07-31.
What interventions are being tested in trial NCT07206589?
The interventions under investigation include: Navigation (OTHER), Endoscopic Procedure (PROCEDURE), Cancer Screening (OTHER), Computer-Assisted Intervention (OTHER), Health Risk Assessment (BEHAVIORAL).
Who is sponsoring clinical trial NCT07206589?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07206589's enrollment target sits among peer trials
1,010 106th of 2000 higher than 1,895 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07191782 · 1,008 participants · NA
Examining the Efficacy of the PRAISE With Coaching Program
- NCT04389632 · 1,006 participants · Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI